INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
We're Built for This
At Abbott, we rise to the world's challenges. We're honored to be one of Fortune's Top 50 Most Admired Companies.
Lifetimes are defined by moments you could never forget.
The just completed year, one which we're relieved to look back on in literal 2020 hindsight, was full of them.
As the COVID-19 pandemic spread to alter nearly every facet of life, the world demanded extensive and expansive coronavirus testing, which couldn't come a moment too soon. At the same time, the world also required remote care via telehealth to connect people with their care providers and doctors at safe, often virtual distances. The world also expected the safe, reliable supplies of nutrition, medicines and medical devices it had come to depend on, no matter what else might be disrupted.
Abbott was built for the very moments that defined 2020.
We stood tall to meet them head on.
The world noticed.
For the first time, Abbott has been named one of the world's 50 Most Admired Companies in Fortune Magazine’s annual rankings, as chosen by the business world, joining an all-star list of well-known household names. Additionally, we were recognized as the most admired company in our industry group again, making it eight years in a row.
For Your Best Health
Helping billions around the world live their best and fullest lives guides everything we do. Because at all times — not just during a pandemic — health and human dignity are inextricably linked and what everyone deserves.
Because our scientific and technical innovations, which touch the lives of 2 billion people now, can never do all the good they're capable of if those who stand to benefit the most don't have access.
Technologies like HeartMate 3, which offered relief and a better life for Tyrone Morris while he was living with heart failure, anticipating a heart transplant that finally arrived. It took some of the weight off the wait for Tyrone so he could just live his life, just like anyone else. He deserves that.
Technologies like FreeStyle Libre 2, which is helping Olympic hopeful Alizée Agier manage her type 1 diabetes while she trains to compete against the most elite athletes in the world with her mind cleared to concentrate on her dreams, not what’s happening with her glucose while she sleeps. She deserves that.
And technologies like the 11 COVID-19 tests we brought to the world throughout 2020 that we're continuing to review and refine as the virus changes. From our molecular tests on our m2000 and ID NOW to antigen and antibody tests. From testing done in high volume labs to our BinaxNOW antigen test which has the ability to be used at home through a virtually guided service. Because humanity deserves it.
There is no question, 2020 presented defining moments throughout its 366 days. Of course, 2020 demanded one day more to leap through. Never a dull moment.
Throughout, we all faced the same questions: Do you rise to the occasion? Or do you surrender to despair?
In the heat of these moments, we never questioned our role and our duty to do our part to help protect the world's health. There was only one choice for us. The challenges may change but we have the same answer we’ve had for more than 130 years.
The past year showed how Abbott "makes a real difference in people's lives," Abbott President and CEO Robert Ford said. "That's a big responsibility. And we're just the team to meet it. We were built for this."
Bring on 2021.
Important safety information
HeartMate 3 w/ Pediatric: ISI
Abbott
One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000
HeartMate3.com
Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure. The HeartMate 3 Left Ventricular Assist System is also indicated for providing short- and long-term mechanical circulatory support in pediatric patients with advanced refractory heart failure.
HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.
HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.
™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third party trademark, which is property of its respective owner.
© 2020 Abbott. All Rights Reserved.
MAT-2012537 v1.0 | Item approved for U.S. use only.
FreeStyle Libre 2 system
The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.*
WARNINGS/LIMITATIONS*: The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit* www.freestylelibre.us for detailed indications for use and safety information.
*For full indications for use and safety information, see more here.
The shape of the circle sensor unit, FreeStyle, Libre, and related brand marks are owned by Abbott. Other trademarks are property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
The BinaxNOW™ COVID-19 Ag Test Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The Abbott RealTime SARS-CoV-2 assay and the Alinity m SARS-CoV-2 assay have not been FDA cleared or approved. These tests have been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories. These tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.